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 Abstract 
 
Background 
Appropriate animal models are required to test novel therapeutics for head and neck 
squamous cell carcinoma (HNSCC) such as near-infrared (NIR) imaging-guided surgery.  
 
Methods 
We developed an optimized animal model of orthotopic HNSCC (in female athymic NMRI 
nude mice) with a prolonged survival time. Resection of the orthotopic tumors was performed 
30 days after implantation with or without the aid of a miniaturized clinical grade NIR optical 
imaging device, after systemic administration of a fluorescent RGD-based probe that targets 
αvβ3 integrin.  
 
Results 
NIR optical imaging-guided surgery increased the recurrence-free survival rate by 50% 
through the detection of fluorescent cancer residues as small as 185 μm; these fragments 
could remain unidentified if resection was performed exclusively under unaided visual 
guidance. 
 
Conclusion 
NIR optical imaging-guided surgery showed an improved HNSCC tumor resection quality in 
our optimized orthotopic animal model.  
 
 
 
 Introduction 
 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide, with 600 000 new cases diagnosed each year. Surgical resection is considered the 
cornerstone of HNSCC treatment and could be associated with radiochemotherapy in some 
cases. Although recent advances in the treatment of HNSCC have improved the survival rate, 
there is a considerable risk of mortality; with more than 300 000 deaths from this disease 
annually (1-3).  
 
The complete excision of HNSCC during surgical resection with negative surgical margins 
improves prognosis and decreases the recurrence rate (4). Intraoperative margin assessment of 
HNSCC is performed by visual inspection and palpation, followed by the selective assessment 
of any suspicious areas using rapid histological evaluation, which can be time consuming and 
sometimes inaccurate. Frequent discrepancies between the selective intraoperative assessment 
and the more comprehensive postoperative pathology margin assessment are not unusual, 
necessitating additional surgeries to achieve negative margins or postoperative 
radiochemotherapy, which can have multiple side effects.  
 
One novel tool to improve tumor resection quality is near-infrared (NIR) optical imaging-
guided surgery, which creates a specific contrast between normal and cancer tissue, thus 
helping to achieve tumor free surgical margins. Multiple animal studies and clinical trials 
have been performed to determine the effectiveness of NIR optical guided surgery at 
optimizing the quality of brain, breast, skin and liver tumors resection, and these studies have 
reported many encouraging results (5-8). One of the most important targets of NIR optical 
imaging-guided surgery is αvβ3 integrin, which plays an important role in cancer-associated 
 angiogenesis, cell proliferation, migration and metastasis. It is widely expressed on neo-
endothelial cells and some cancer cells, such as HNSCC (9-13). RAFT-c(-RGDfK-)4 
(regioselectively addressable functionalized template-arginine-glycine-aspartic acid) is a 
peptide-like scaffold that contains four cyclo(-RGDfK-) (cRGD) motifs, and this molecule 
has been shown to target αvβ3 integrin in vitro and in vivo. This peptide is also particularly 
efficient at targeted delivery of drugs and imaging contrast agents.(14-17) 
 
The development and evaluation of novel anticancer agents or new surgical techniques for 
HNSCC treatment require the use of an appropriate animal model that must be representative 
and reproducible and can accurately recapitulate the disease process. 
 
Here, we developed an experimental xenograft orthotopic animal model of HNSCC that can 
be used to test novel molecular therapeutics or surgical tools. In this model, orthotopic tumor 
implantation and resection was performed in a novel way. The aim of the development of our 
model is to assess the role of NIR optical imaging-guided surgery in the surgical resection of 
HNSCC tumors, by using a miniaturized NIR optical device designed for oral oncologic 
procedures (18) and fluorescent RAFT-c(-RGDfK-)4 injection. Our orthoptopic model 
allowed us to test the benefits of NIR optical imaging-guided tumor resection compared to 
macroscopic tumor resection in the detection of cancer residues and its effect on the 
recurrence-free survival rate of mice.  
 
Materials and methods 
 
Cell line: 
 This study was conducted using the human head and neck squamous cell carcinoma cell line 
CAL33, which was stably transfected with the pLenti-luciferase vector. This cell line was 
obtained from the Antoine-Lacassagne Center, Nice, France (19). The cell line was 
maintained as a monolayer culture in DMEM supplemented with 10% FBS (v/v) in a 
humidified incubator (Sanyo, Japan) at 37 °C in an atmosphere containing 8% CO2. CAL33 
cells were used in vivo for establishing subcutaneous tumors from which tumor fragments 
were obtained for orthotropic tumor implantation. In addition to luciferase expression by these 
cells which allows bioluminescence imaging, they represent an adequate cellular model for 
HNSCC as they show positive expression of EGFR, IGF1R and NRP1 like in some types of 
head and neck cancers (20-24).  
 
Molecule 
AngioStamp™ 800 (Fluoptics, Grenoble, France) was injected into the tail vein of the mice. 
This imaging agent is a tetravalent RGD-based peptide (RAFT-c(-RGDfK-)4) that targets αvβ3 
integrin. It is labeled with a NIR organic fluorophore with an absorbance and an emission 
maxima of 781 nm and 794 nm respectively to allow in vivo NIR fluorescence imaging using 
the NIR fluorescence imaging system described below (15, 17, 25-27).  
 
Flow cytometry 
The expression of αvβ3 integrin and the binding of RAFT-c(-RGDfK-)4 to the CAL33 cell line 
were analyzed by flow cytometry. Briefly, CAL33 cells were harvested, washed with PBS 
containing 1 mM CaCl2 and 1 mM MgCl2 (PBS Ca2+/Mg2+) and fixed in 2% 
paraformaldehyde for 15 minutes at room temperature. Cell fixation was done exclusively for 
the assessment of αvβ3 integrin expression.  After washing twice with PBS Ca2+/Mg2+, the 
cells were incubated with an anti-human CD51/CD61 mouse phycoerythrin-conjugated 
 antibody (clone 23C6, Pharmingen, BD Bioscience) or with the RAFT-c(-RGDfK-)4 for 1 
hour at 4 °C for the former and at 37 °C for the later, then washed again and resuspended in 
PBS Ca2+/Mg2+ at 4 °C. Analysis was performed using a BD Accuri C6 flow cytometer (BD 
Biosciences, US) and the CFlow Plus software. The results are reported as the mean 
fluorescence intensity. The RGD-based peptide RAFT-c(-RGDfK-)4 used in the flow 
cytometry analysis was labeled by Cy5 to make it compatible with the laser wavelength and 
filters of BD Accuri C6 flow cytometer. Cy5-labeled RAFT-c(-RGDfK-)4 was synthesized 
according to previously reported procedures (28). 
 
Animals 
All animal experiments were performed in agreement with the EEC guidelines and the 
Principles of Laboratory Animal Care (NIH publication 14, nos. 86–23, revised 1985); the 
protocol was approved by the Animal Care and Use Committee (Comité d’éthique en 
expérimentation animale de Grenoble). Female athymic NMRI nude mice (Janvier, Le 
Genest-Isle, France) were maintained under specific pathogen-free conditions. The animals 
were housed and optical imaging was performed at the small animal optical imaging platform 
OPTIMAL of INSERM U823 Institute.  
 
Subcutaneous tumor implantation and excision 
Human CAL33 cells were harvested, and 10
6
 cells in PBS were injected subcutaneously into 
the flank of the mice for heterotropic establishment of tumors. Tumor growth was quantified 
by measuring the tumors in two dimensions with a Vernier calliper twice a week. The tumor 
volume was calculated using the following equation: a x b
2
 x 0.4, where a and b are the 
largest and smallest diameters, respectively. When the tumor volumes reached 750 mm
3
, after 
approximately 14 to 16 days, the tumors were excised by direct approach under general 
 anesthesia with isoflurane/oxygen; 3.5% anesthesia was used for induction, and 1.5% was 
used for the maintenance of anesthesia. The mice were then euthanized by cervical dislocation. 
Fragments from these tumors were subsequently used for orthotopic tumor implantation as 
described below.  
 
Orthotopic tumor implantation 
Under general anesthesia, obtained by intraperitoneal injection of Domitor (Pfizer, Orsay, 
France) and Imalgene (Merial, Lyon, France), a small incision was performed on the inner 
aspect of the mouse’s cheek. A tumor fragment with a diameter of 0.5 mm, obtained from the 
subcutaneous tumours, was implanted through the incision, and the incision was closed using 
PDS™ II (polydioxanone) 5-0 monofilament synthetic absorbable suture. The growth of the 
orthotopic tumors was examined each week using non-invasive bioluminescence imaging, and 
the tumors reached the maximal size compatible with the mouse’s well-being 30 days after 
implantation. 
 
Bioluminescence imaging  
The mice received an intraperitoneal injection of luciferin (150 mg/kg) 5 min before the 
bioluminescence imaging, which was carried out using an IVIS Kinetic device (Caliper Life 
Sciences). This enabled the quantification and tracing of the bioluminescent signal during 
orthotopic tumor development and the early detection of recurrence after tumor resection. 
Semiquantitative data were obtained from the bioluminescence images within demarcated 
regions of interest in the area to be quantified. The results were expressed as the number of 
photons per second. 
 
NIR fluorescence imaging 
 AngioStamp™ 800 was injected into the tail vein of the mice at a dose of 10 nmol per mouse 
16 to 24 hours before fluorescence imaging to obtain the maximal fluorescence signal 
intensity at the tumor site. Moreover, the AngioStamp™ 800 biodistribution as well as the 
orthotopic tumors fluorescence kinetics was performed. NIR fluorescence imaging was 
performed using the FluoStick™ Clinical System (Fluoptics, Grenoble, France). This novel 
commercial fluorescence imaging system has been miniaturized and optimized for oral 
oncologic procedures in humans. It excites fluorescence at 750 nm and detects the emitted 
light at wavelengths greater than 800 nm. 
 
Orthotopic tumor resection 
Orthotopic tumor resection was performed under visual guidance or through the aid of NIR 
optical imaging. Under general anesthesia (intraperitoneal injection of Domitor and Imalgene), 
we performed a direct approach through an incision on the outer aspect of the cheek to obtain 
a large surgical field that permitted tumor dissection and resection. Initially, the tumor was 
exposed, and the fluorescence of the head and neck region was obtained. Intentionally, 90% 
of the tumor was removed under visual guidance, without NIR optical imaging, and a rim of 
tissue (10%) was left behind to simulate residual disease and to investigate the ability of the 
fluorescence imaging to detect smaller disease foci. The rim of the residual tumor tissue was 
then removed under visual guidance to achieve a complete macroscopic tumor resection. 
After excision, fluorescence imaging was repeated. In this step, any residual fluorescent tissue 
unintentionally left behind was removed with the help of the fluorescence imaging guidance 
system. Non-fluorescent control tissue fragments were also taken from the tumor bed. One 
dose of 0.1 mg/kg buprenorphine (RB Pharmaceuticals, France) was injected subcutaneously 
to reduce postoperative pain after orthotopic tumor resection. The fluorescence of the tumor, 
residual fluorescent tissue and control tissue were measured ex vivo. 
  
Analysis of NIR fluorescence data 
The fluorescent data collected using the FluoStick™ Clinical System were quantified with the 
WASABI Imaging software V.1.5.0.5 (Hamamatsu Photonics GmbH, Germany) and 
Microsoft Excel. The fluorescence intensity value of the different tissues was defined as the 
mean fluorescence intensity of the region of interest minus the mean fluorescence intensity of 
the background divided by the exposure time in milliseconds, resulting in the relative light 
unit per pixel per millisecond (RLU/pixel/ms). 
 
Mouse follow-up after tumor resection 
Four mice were used experimentally to develop the orthotopic model. The rest of mice (n=24) 
were examined and weighed regularly after orthotopic tumor excision to detect tumor 
recurrence through repeated clinical examination and bioluminescence imaging in order to 
compare the recurrence-free rate of the macroscopic tumor resection and the NIR 
fluorescence imaging-guided tumor resection. Any mouse that showed signs of tumor 
recurrence was euthanized by cervical dislocation. Mice without relapse were followed up for 
two months after tumor excision and were then euthanized and dissected post-mortem to 
search for infra-clinical recurrence. 
 
Histopathological and immunohistochemical analyses 
Surgical specimens were separated into two samples for histopathological and immuno-
histological analyses of the αvβ3 integrin expression level. A portion of the samples was fixed 
in formaldehyde, embedded in paraffin and cut into 7 μm slices for hematoxylin and eosin 
(H.E.) staining of the orthotopic tumors, residual fluorescent tissues and non-fluorescent 
control tissues. Histological examination was performed under an Olympus BX41 Laboratory 
 Microscope. Any tumor foci identified in the residual fluorescent tissues were measured using 
the Image J 1.46r software. Other samples were frozen in isopentane and underwent shock 
freezing in liquid nitrogen. These samples were cut into 8 μm slices (microcryotome) and 
stored at −80 °C until fixation and staining. After the frozen slices were thawed at room 
temperature, they were fixed in acetone. Immunostaining with a mouse anti-human integrin 
αvβ3 monoclonal antibody (clone MAB1976, 1:500; Millipore) was performed on the acetone-
fixed cryosections of the orthotopic tumours using the M.O.M. immunodetection (peroxidase) 
Kit (Vector laboratories, Inc., Burlingame, CA). Staining was performed using liquid DAB 
and a substrate chromogen system (Dako, North America, Inc., CA). The nuclei were 
counterstained with hematoxylin. 
 
Statistical analysis 
Statistical analysis was performed using the coefficient of determination R
2
 in the GraphPad 
Prism 5 software (GraphPad Software, Inc.). Statistical significance was assigned for values 
of p < 0.05. 
 
Results 
 
Development of an optimized head and neck cancer orthotopic animal model 
Twenty eight mice were implanted with a tumor fragment obtained from subcutaneous 
CAL33 tumors (fig. 1a and 1b). All mice survived after the orthotopic tumor implantation, 
and there were no complications during the surgical procedure. Minimal cheek swelling and 
inflammation was observed after implantation, and this regressed spontaneously after one day. 
The mice did not exhibit weight loss, and there was no change in feeding during tumor 
development (fig. 1f). Orthotopic tumors could be observed macroscopically from day 10 to 
 12 following implantation (fig. 1c). The mice underwent orthotopic tumor resection on the 
day 30 day after implantation (fig. 1d). There were no complications during tumor excision 
except that special care had to be taken to ensure hemostasis, by applying pressure with a 
cotton swab to stop the bleeding and to prevent blood inhalation by the mice during surgery. 
One mouse developed a cheek hematoma that spontaneously resolved postoperatively. 
Minimal transient weight loss of about two grams was observed in some mice following 
tumor resection owing to difficulty in feeding due to the presence of cheek inflammation; this 
condition spontaneously resolved after 3 days (fig. 1f), and weight gain returned to its normal 
rate within 2 days of explantation. All mice survived after tumor resection, and complete 
wound healing was finished after 5-7 days (fig. 1e). Pathological analysis of resected 
orthotopic tumors showed the characteristics of moderately differentiated HNSCC (fig. 2a). 
 
Expression of αvβ3 integrin in the CAL33 cell line 
Flow cytometry analysis showed a positive in vitro expression of αvβ3 integrin by 98.5 % of 
the CAL33 cells (fig. 2b). RAFT-c(-RGDfK-)4 showed a positive binding to 96.2 % of these 
cells (fig. 2c). In vivo expression of αvβ3 integrin in the human CAL33 cell line was also 
confirmed by immunohistochemical labelling of the tumor sections; positive staining in tumor 
samples (fig. 2d) and negative staining in control tissue (fig. 2e). 
 
These results were essential to target the orthotopic tumors developed from this cell line using 
the RGD-based probe AngioStamp™ 800 NIR Molecular Imaging Agent, which binds 
specifically to αvβ3 integrin. 
 
Fluorescence imaging is a valuable tool for head and neck tumor resection  
 The biodistribution of AngioStamp™ 800 showed high concentration in the kidney and in the 
orthotopic tumor 24 hours after intravenous injection (fig 3a). Importantly, elevated tumor 
tumor to background fluorescence ratios were obtained 16 to 24 hours after AngioStamp™ 
800 injection (fig. 3b). Two independent group of mice (n=6 in each group) underwent tumor 
resection with the aid of fluorescence imaging as described in the materials and methods 
section. All orthotopic tumors were fluorescent (fig. 4a) with a very elevated contrast of 65 (± 
22) due to the high fluorescence ratio of the tumor to the surrounding muscle. After 
macroscopic excision of 90% of the tumor, the FluoStick™ Clinical System device (fig. 4f) 
detected the residual 10% of the tumor (fig. 4b). This confirmed that fluorescence imaging 
could efficiently detect small disease foci. After removal of the 10% macroscopic tumor 
residue under visual guidance, residual fluorescent tissue 0.2-1.8 mm in diameter was 
unintentionally left behind in all of the mice (fig. 4c). These tissue foci (n=37) were removed 
under fluorescence imaging guidance. No fluorescent signal could be detected in the tumor 
bed after the residual fluorescent tissue excision (fig. 4d), except for the autofluorescence 
signal of the mandible and of the skin that was observed in a few mice. All resected tissue foci 
were significantly fluorescent ex vivo compared to the control tissue (fig. 4e). 
Histopathological analysis (fig. 5) showed that tumor foci were present in 94.6 % of the 
residual fluorescent tissues. For each mouse, at least one fluorescent residue revealed a tumor 
focus. Histological examination showed that fluorescence imaging could detect tumor foci as 
small as 185 μm (fig. 5a). There was a positive correlation between the diameter of the tumor 
focus and the fluorescence intensity of the residual tissue containing the focus (fig. 5b). 
Moreover, the fluorescent probe provided good contrast between residual cancer tissue and 
normal tissue with a residual cancer tissue to background tissue fluorescence ratio of 10 (±6).  
 
Effect of NIR optical imaging-guided surgery on recurrence-free survival rate 
 The recurrence-free survival rate of mice after NIR optical imaging-guided surgery was 
compared to that after visually guided macroscopic tumor resection. Bioluminescence was 
performed regularly after tumor resection (fig. 6a). In two independent groups where the 
resection of orthotopic tumors was performed under visual guidance (n=6 in each group), the 
macroscopic recurrence of the disease was mostly observed 3-4 weeks after tumor excision in 
75 % (± 5) of the mice, in contrast to 25 % (± 5) in the two groups where NIR optical imaging 
was used during tumor resection (n=6 in each group) (fig. 6b-d). Relapse was confirmed by 
bioluminescence, which showed an early gradual increase of the bioluminescent signal. No 
tumor was found on the post-mortem dissection of mice that showed no signs of macroscopic 
recurrence. Therefore, we found that NIR optical imaging-guided surgery increased the 
recurrence-free survival rate by 50% two months after tumor resection (fig. 6e).  
 
Discussion 
 
The advantage of orthotopic HNSCC animal models over subcutaneous models is that they 
provide specific interactions between the cancer cells and their native environment. These 
interactions can influence the molecular, pathological, and clinical features of the orthotopic 
tumors, rendering them representative of human HNSCC tumours (29-31).  
 
Mice are one of the preferred animal species in biomedical research because they are small in 
size, easy to handle and relatively inexpensive. Several methods have been used to develop 
orthotopic HNSCC mouse models. One of these methods is based on the repetitive local 
application of carcinogenic agents, such as 7,12-dimethylbenz[a]anthracene (DMBA), 4-
nitroquinoline 1-oxide (4NQO), 12-O-tetradecanoylphorbol-13-acetate, benzo[a]pyrene, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone and nitrosonornicotine, in the oral cavity. The 
 major disadvantage of this method is that it takes between 12 and 34 weeks to develop 
tumours with a poor penetrance. Additionally, these tumors do not mimic the invasive 
pathology of HNSCC in humans (29-32). In a transgenic mouse model of HNSCC, the keratin 
5 (K5) or keratin 14 (K14) promoters are used to overexpress the oncogene K-ras
G12D
 in the 
oral epithelium to induce squamous cell carcinoma (33-34). Although these transgenic models 
appear to reproduce some clinical characteristics of HNSCC, one major point that should be 
taken into consideration is that no single gene is predominantly associated with the HNSCC 
carcinogenic process in humans. In addition, the frequency of K-ras mutations in HNSCC is 
relatively low (31). Finally, one of the most important methods of inducing head and neck 
tumors in animals is through the orthotopic xenograft of HNSCC by injecting the cancer cells 
into the tongue or mouth floor of the mouse. The major disadvantage of this model is that 
animals have to be euthanized on day 10 to 12 after tumor cell injection because of rapid 
tumor growth that prevents correct feeding by the animals, resulting in unethical suffering (21, 
35-36). This short period with in situ tumors does not allow for the adequate long-term 
efficacy evaluation of new treatments. Additionally, due to the disruption of vital structures in 
the oral cavity during tumor resection, the mice have to be euthanized at the end of the 
surgery, which prevents the evaluation of the post-operative benefits and effects of novel 
surgical and therapeutic tools.  
 
We developed a novel method of orthotopic HNSCC tumor implantation and resection in 
female athymic NMRI nude mice. Our model allowed us to obtain a period of 30 days with in 
situ tumors. Our method used tumor fragment implantation instead of direct cellular injection 
and was developed in other types of small animal xenograft tumor models for gastric, hepatic 
and oesophageal cancers (37-39). This method prevented the cancer cell dissemination 
created by the hydrostatic pressure of the syringe during injection, which results in the rapid 
 development of large tumors that reduce mice survival to 10-12 days (29-31). All mice that 
underwent tumor fragment implantation developed an orthotopic tumor. A major advantage of 
our model is that orthotopic tumor resection can be performed 30 days after implantation. 
Furthermore, the postoperative survival rate reached 100% because the site of orthotopic 
tumor development and our surgical resection technique preserved the vital structures of the 
mouse oral cavity. This allowed us to follow up with the mice when investigating novel 
surgical or medical treatments to establish efficacy, toxicity, and survival studies. 
 
The prognosis of HNSCC depends on many factors, such as the TNM staging, the localization 
of the tumor, the level of differentiation and the quality of the surgical margins. In HNSCC, as 
in other solid tumors, complete tumor resection improves the patient’s outcome. Positive 
surgical margins cannot be compensated by adjuvant radiotherapy/chemotherapy, and they 
increase the rate of tumor recurrence and reduce the overall survival rate (4). In real life 
surgical practice, to ensure tumor removal, the surgeon excises a safe margin of 0.5 to 1.0 cm 
around the tumor. This margin is difficult to determine macroscopically at the deepest part of 
the tumor, which is in contact with the surgical bed, because resection at this site depends 
mainly on palpation and not on visual guidance. The pathologist then uses frozen sections to 
confirm that the margins of resection do not contain cancerous tissue. Unfortunately, frozen 
sections removed at the level of the surgical bed lead to important sampling errors because of 
the increased difficulty in margin relocation. Consequently, small residual cancer foci can be 
left behind, resulting in an increased risk of tumor recurrence (40-41).  
 
The introduction of real-time imaging technologies, such as NIR fluorescence, into the 
operating room has the potential of bridging the gap between radiology and surgery, resulting 
in intraoperative image-guided surgery that improves the quality of solid tumor resection. 
 This type of imaging requires specific targeted contrast agents that bind to the cancer cells and 
generate a significant signal to noise ratio between the tumor and the surrounding normal 
tissue. Various cell surface molecules, including epidermal growth factor receptor, Her-2/Neu, 
αvβ3 integrin, urokinase plasminogen activator receptor, mucin 1, carcinoembryonic antigen, 
and the folate receptor, have been investigated for targeted imaging (8). Multiple studies have 
been performed in animals and humans to evaluate the role of NIR optical imaging-guided 
surgery in solid tumor resection. In preclinical animal models, NIR optical imaging-guided 
surgery was used to optimize the resection quality of breast, ovarian, brain and colon tumors 
or metastases. In these models, αvβ3 integrin, which is overexpressed in tumor cells and in 
neo-endothelial cells, was the most common receptor targeted in NIR optical imaging-guided 
surgery. AngioStamp™ 800, the commercial version of the RAFT-c(-RGDfK-)4 peptide 
coupled with a fluorophore, was commonly used to target αvβ3 integrin. NIR optical imaging-
guided surgery in these models improved the tumor resection quality and the detection and 
excision of metastases (5, 42-44). Other studies have also been performed in humans to assess 
the benefit of NIR optical imaging-guided surgery in head and neck cancer resection. In most 
of these studies, ICG (indocynaine green) was used as a fluorescent tracer. Although ICG is 
considered a blood pool agent that is not inherently specific for any tumor, it is the only NIR 
fluorescent agent that has been used in clinical applications because it is EMA (European 
Medicines Agency) and FDA (US Food and Drug Administration) approved. Yoakoyama et 
al. used ICG to delineate head and neck tumors and lymph node metastases in humans 30 to 
60 minutes after intravenous administration (45). All tumors and lymphatic metastases 
displayed bright fluorescence emissions that clearly contrasted with the normal structures. 
Fluorescence imaging was very useful to detect metastatic lymph nodes that were not palpable, 
and not visible macroscopically, in the retropharyngeal space. Despite of these encouraging 
results, precautions have to be taken in tumor margin demarcation using ICG because 
 accumulation of ICG may not be limited to cancerous tissues. In fact, ICG would also be 
expected to accumulate in inflammatory tissues and areas of surgical trauma that could partly 
hamper specificity in the initial phase of enhanced permeability and retention effect. However, 
these effects occur at much lower levels and retention in tumors is greatly increased owing to 
defective architecture of lymphatic drainage (46-47). For these reasons, a targeted probe, like 
the one that we used in our study, would provide real-time, intra-operative distinction of the 
molecular edge between cancer and adjacent normal tissue. The benefit would be to 
potentially decreasing the incidence of a positive surgical tumor margin. 
 
AngioStamp™ 800 that targets specifically αvβ3 integrin was used in our orthotropic model 
because αvβ3 integrin is expressed in HNSCC tumors (9-13), as well as in the CAL33 HNSCC 
cell line. We previously developed a miniaturized NIR optical imaging prototype adapted to 
the geometry of the oral cavity (18). In the present work, we used a commercial clinical grade 
device called FluoStick™, which was also developed for use in oral oncologic procedures in 
humans. After macroscopic removal of the orthotopic tumors, very small residual fluorescent 
tissues of 0.2-1.8 mm in diameter were unintentionally left behind, and these foci were 
detected in the tumor bed. These fluorescent residues were removed separately, and cancer 
foci as small as 185 μm were identified in these extracted samples; a positive correlation 
between the intensity of the fluorescence and the size of the cancer focus existed. Indeed, the 
amount of bound AngioStamp™ 800 increases as the number of malignant and neo-
endothelial cells in the tumor foci increases. Additionally, we showed that NIR optical 
imaging-guided surgery improved the recurrence-free survival rate by 50% two months after 
tumor resection. Because NIR optical imaging-guided surgery improved the quality of 
HNSCC resection and decreased the cancer recurrence rate in our orthotopic animal model, 
this valuable tool could be used in humans to optimize HNSCC resection, especially at the 
 deepest part of the tumor, through the identification of small tumor foci, as shown in our 
model.  
 
Conclusion 
 
We developed a reproducible orthotopic mouse model of HNSCC with mice surviving up to 
30 days with an in situ tumor, as well as after tumor resection. Our orthotopic model currently 
provides the most accurate reflection of the clinical situation and allows efficacy, toxicity, and 
survival studies of novel medical or surgical treatments for HNSCC. This model allowed us to 
demonstrate that NIR optical imaging-guided surgery improves the quality of HNSCC 
resection by detecting fluorescent cancer foci that could remain unidentified if resection was 
performed exclusively under visual guidance. This preclinical stage is the first step toward 
testing NIR optical imaging-guided surgery for HNSCC in humans.  
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